The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) non-small cell lung cancer (NSCLC).
 
Byoung Chul Cho
Leadership - Interpark Bio; J Ints Bio
Stock and Other Ownership Interests - Bridgebio; Cyrus therapeutics; Gencurix; Interpark Bio; J INTS BIO; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - Abion; AstraZeneca; BeiGene; Blueprint medicines; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb; CJ bioscience; CureLogen; Cyrus therapeutics; GI Cell; Guardant Health; Hanmi; Imnewrun; inno.N; Janssen; Kanaph Therapeutics; Lilly; Medpacto; MSD; Novartis; Onegene Biotechnology; Ono Pharmaceutical; Oscotec; Pfizer; RandBio; Roche; Takeda; Yuhan
Research Funding - Abbvie; Abion; AstraZeneca; Bayer; Blueprint medicines; Boehringer Ingelheim; Bridgebio; CHA Bundang Medical Center; Champions Oncology; CJ bioscience; CJ Blossom Park; Cyrus Therapeutics; Dizal Pharma; Dong-A ST; Genexine; GI Cell; GI Innovation; Hanmi; Illumina; ImmuneOncia; Interpark Bio; J Ints Bio; Janssen; Kanaph therapeutics; LG Chem; Lilly; Mogam Biotechnology Research Institue; MSD; Novartis; Nuvalent, Inc.; Oncternal Therapeutics; Ono Pharmaceutical; Oscotec; Regeneron; Therapex; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology; Crown Bioscience; Imagen
Other Relationship - DAAN Biotherapeutics
 
Chao-Hua Chiu
Honoraria - Amgen; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Janssen; Lilly; Merck KGaA; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Shionogi; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen; Lilly; Merck KGaA; MSD; Novartis; Roche
 
Erminia Massarelli
Honoraria - AstraZeneca; Merck
Consulting or Advisory Role - Abbvie; Bristol Myers Squibb Foundation; Daiichi Sankyo Co.; Genentech/Roche; Janssen Scientific Affairs; Lilly; Merck; Sanofi
Speakers' Bureau - AstraZeneca; Lilly; Merck; Mirati Therapeutics; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Merck (Inst); Pfizer (Inst); Tessa Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Pfizer
 
Gary L Buchschacher
Research Funding - AstraZeneca (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Koichi Goto
Honoraria - Amgen; Amgen; Amoy Diagnostics; AstraZeneca Japan; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health; Janssen; Life Technologies; Lilly Japan; Medpace; Merck; Novartis; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Bayer; Janssen; Lilly Japan; Medpace
Research Funding - Amgen (Inst); Amgen (Inst); Amgen Astellas BioPharma (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Eisai (Inst); Ignyta (Inst); Janssen (Inst); Kissei Pharmaceutical (Inst); Kyowa Kirin Co., Ltd. (Inst); Lilly Japan (Inst); Loxo (Inst); MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (Inst); Merck (Inst); Merus (Inst); MSD K.K. (Inst); NEC Corporation (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shanghai HaiHe Pharmaceutical (Inst); Spectrum Pharmaceuticals (Inst); Sumitomo Dainippon Pharma Co., Ltd. (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Thermo Fisher Scientific (Inst); Turning Point Therapeutics (Inst)
 
Tobias R. Overbeck
Honoraria - AstraZeneca; BMS GmbH & Co. KG; Boehringer Ingelheim; Lilly/Merck; MSD; Novartis; Roche; Takeda; Tesaro/GSK
Consulting or Advisory Role - AstraZeneca; BMS GmbH & Co. KG; Boehringer Ingelheim; Lilly/Merck; MSD; Novartis; Roche; Takeda; Tesaro/GSK
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Janssen-Cilag; Lilly O.; Roche
 
Herbert H. F. Loong
Consulting or Advisory Role - Boehringer Ingelheim; Celgene; Eisai; GlaxoSmithKline; Guardant Health; Illumina; Lilly; Novartis; Roche/Genentech; Takeda
Speakers' Bureau - Bayer; Guardant Health; Ignyta; Novartis
Research Funding - MSD Oncology (Inst)
Travel, Accommodations, Expenses - Bayer; MSD Oncology; Pfizer; Roche
 
Cheng E. Chee
Honoraria - Amgen; AstraZeneca; Pierre Fabre; Roche/Genentech
Consulting or Advisory Role - Guardant Health AMEA; Merck
 
Pilar Garrido
Employment - Teva (I)
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Boehringer Ingelheim (I); Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Gebro Pharma (I); GlaxoSmithKline; IO Biotech; Janssen Biotech (I); Janssen Oncology; Lilly; Merck KGaA; MSD Oncology; Nordic Group (I); Novartis/Pfizer; Pfizer; Roche Pharma AG; Sanofi/Regeneron; Takeda
Speakers' Bureau - AstraZeneca; BMS; Boehringer Ingelheim; Boehringer Ingelheim (I); Janssen (I); Janssen Oncology; Medscape; MSD Oncology; Nordic Group (I); Novartis; Pfizer; Roche Pharma AG; Takeda; touchIME
Travel, Accommodations, Expenses - AstraZeneca Spain
Other Relationship - IO Biotech; Janssen Oncology; Novartis
 
Sebastian Heinzmann
Employment - Roche
Stock and Other Ownership Interests - F. Hoffmann LaRoche
Travel, Accommodations, Expenses - F. Hoffmann LaRoche
 
Walter Bordogna
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Harald Zeuner
Employment - Roche
 
Stuart Osborne
Employment - F. Hoffmann LaRoche
Stock and Other Ownership Interests - F. Hoffmann LaRoche; Novartis
 
Tom John
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech
Consulting or Advisory Role - Amgen (Inst); AstraZeneca; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Gilead Sciences; Ignyta; Merck KGaA; MSD Oncology; Novartis; Pfizer; PharmaMar (Inst); Roche/Genentech; Specialised Therapeutics
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche; Roche